N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.

[1]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[2]  R. Berger,et al.  Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. , 2002, European heart journal.

[3]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.

[4]  W. Kübler,et al.  Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. , 2002, Journal of the American College of Cardiology.

[5]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[6]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[7]  A. D. Cunningham,et al.  Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population , 2001, Heart.

[8]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[9]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[10]  R. Novick,et al.  The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  D. Mancini,et al.  Peak VO(2): a simple yet enduring standard. , 2000, Circulation.

[12]  K. Pardaens,et al.  Peak oxygen uptake better predicts outcome than submaximal respiratory data in heart transplant candidates. , 2000, Circulation.

[13]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[14]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[15]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[16]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[17]  M. Komajda,et al.  Prognostic value of plasma endothelin-1 in patients with chronic heart failure. , 1997, European heart journal.

[18]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[19]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[20]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[21]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.